CHICAGO, Sept. 29, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead Sciences (Nasdaq:GILD-Free Report), Bristol-Myers (NYSE:BMY-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report), AbbVie (NYSE:ABBV-Free Report) and Medivation (Nasdaq:MDVN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday's Analyst Blog:
New Gilead HIV Drugs Cleared by FDA
Good news flowed in at Gilead Sciences (Nasdaq:GILD-Free Report) with the FDA clearing two of its HIV drugs — Tybost (cobicistat) and Vitekta (elvitegravir). Tybost has been approved in combination with other antiretroviral agents for treating patients with HIV-1 infection. Cobicistat acts as a "boosting" agent, whose addition causes blood levels of protease inhibitors, such as Bristol-Myers' (NYSE:BMY-Free Report) Reyataz and Johnson & Johnson's (NYSE:JNJ-Free Report) Prezista to increase, thereby enabling the HIV therapy to be dosed once daily.
Vitekta, which works by interfering with HIV replication, gained FDA approval for use in treatment experienced HIV-1 infected adults in combination with an HIV protease inhibitor co-administered with AbbVie's (NYSE:ABBV-Free Report) Norvir (ritonavir) and other antiretroviral treatments.
Second Time Lucky for These Drugs
The path leading to FDA approval has been anything but smooth for Tybost and Vitekta. Last year, the FDA declined to approve the drugs for use as part of HIV therapy regimens and issued complete response letters (read more: Double Setback for Gilead). Following the receipt of the complete response letters, Gilead resubmitted the new drug applications and the FDA assigned target dates of Oct 3 and Oct 4 for deciding on Tybost and Vitekta respectively. However, the U.S. regulatory body arrived at its decision well before the PDUFA dates.
EU Approval Already in the Bag
The EU approval of these drugs has however been smooth. Tybost was cleared in the EU in Sep 2013. European approval for Vitekta was gained in Nov 2013. The sales potential of the HIV drugs would increase following their clearance in the U.S.
Gilead carries a Zacks Rank #1 (Strong Buy). Medivation (Nasdaq:MDVN-Free Report) is an equally well-ranked stock in the health care space.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on GILD - FREE
Get the full Report on BMY - FREE
Get the full Report on JNJ - FREE
Get the full Report on ABBV - FREE
Get the full Report on MDVN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
Share this article